STOCK TITAN

Enveric Biosciences, Inc. - ENVB STOCK NEWS

Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.

Enveric Biosciences, Inc. (ENVB) is a pioneering biotechnology company committed to the development of innovative neuroplastogenic small-molecule therapeutics aimed at treating mental health conditions such as depression, anxiety, and addiction disorders. Headquartered in the United States, Enveric is at the forefront of mental health research, with a focus on non-hallucinogenic solutions.

The company's flagship program, EB-003, represents a novel approach to tackling challenging mental health disorders. Unlike traditional treatments, EB-003 promotes neuroplasticity without causing hallucinations, providing a safer and potentially more effective option for patients.

Another key project in Enveric's pipeline is EB-002, previously known as EB-373. This next-generation synthetic prodrug of psilocin is being developed to offer new hope in the treatment of psychiatric disorders. With an emphasis on rigorous scientific research and clinical trials, Enveric strives to deliver breakthrough therapies that can significantly improve patients' quality of life.

Enveric's strategic vision includes forming partnerships and collaborations to enhance its research capabilities and accelerate the development of its therapeutic programs. Highlighting its commitment to innovation, the company is also investing in cutting-edge technologies such as artificial intelligence (AI) to further its research and development efforts.

Financially, Enveric Biosciences has been transparent about its funding efforts, ensuring that it maintains a robust financial foundation to support its research initiatives. With a strong commitment to ethical practices and patient-centric solutions, Enveric is emerging as a key player in the biotech sector, focused on addressing some of the most pressing mental health challenges of our time.

Rhea-AI Summary
Enveric Biosciences (ENVB) has received a Notice of Allowance from the USPTO for a patent application pertaining to its EVM301 Series of molecules, aiming to develop treatments for mental health disorders. The company is focused on developing compounds that engage neurotransmitter receptors to promote neuroplasticity, with the goal of generating therapeutic benefit without inducing hallucinations. Enveric has filed multiple composition of matter patent applications with the USPTO, and to date, has received nine Notices of Allowance for patent applications claiming compounds in the EVM201 and EVM301 Series.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.44%
Tags
none
-
Rhea-AI Summary
Enveric Biosciences (ENVB) announces the development of lead therapeutic candidate EB-373, a novel psilocin prodrug, to be published in the Journal of Medicinal Chemistry. The compound offers potential benefits for the treatment of anxiety disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
none
-
Rhea-AI Summary
Enveric Biosciences (ENVB) presented two posters at the Canadian Chemical Engineering Conference (CSChE 2023) showcasing the biocatalytic production of MDMA and other phenylpropylamine derivatives, as well as a synthetic biology platform for the production of novel indolethylamine derivatives as drug candidates to treat anxiety and depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none
Rhea-AI Summary
Enveric Biosciences, Inc. (NASDAQ: ENVB) announced significant progress in the development of neuroplastogenic small-molecule therapeutics for mental health disorders. Key highlights include the completion of several initiatives to strengthen the company's IP estate, the publication of leading scientific research, and the filing of patents for novel drug candidates and compositions of matter. The company also reported favorable results from preclinical studies and showcased the leading drug discovery and research engine behind its EVM301 Series of compounds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Summary
Enveric Biosciences has received a Notice of Allowance from the US Patent and Trademark Office for a patent application involving their lead clinical candidate, EB-373. The patent includes composition of matter claims for a family of novel prodrug derivatives of psilocin. Enveric has filed multiple composition of matter patent applications for psilocin prodrugs and has obtained seven NoAs so far. The company aims to establish a robust intellectual property position to develop improved treatments for mental health disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
none
-
Rhea-AI Summary
Enveric Biosciences CEO to present at Centurion One 5th Global Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
conferences
Rhea-AI Summary
Enveric Biosciences initiates GLP-toxicology and safety pharmacology studies for lead prodrug candidate EB-373
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
none
-
Rhea-AI Summary
Enveric Biosciences presents research on neuroplastogenic therapeutics at Neuropsychiatric Drug Development Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.04%
Tags
none
-
Rhea-AI Summary
Enveric Biosciences has reached a milestone in its Psybrary™ portfolio, surpassing 1000 synthesized compounds, which is accelerating its drug discovery process. The company anticipates nominating a lead development candidate in early 2024 for its EVM301 program, targeting major undertreated mental health indications. The novelty and diversity of the molecules in the portfolio enable robust IP-based protection strategies and potential collaborations for accelerated development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
none
Rhea-AI Summary
Enveric Biosciences announces the discovery of a key enzyme from cane toad and successful development of a bioproduction platform for novel indolethylamines with potential use in psychiatric medicine. The enzyme is a superior biocatalyst and has applications in the synthesis and screening of psychedelic-inspired medicines. This innovative method establishes a new approach for the production, purification, and screening of drug candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
none

FAQ

What is the current stock price of Enveric Biosciences (ENVB)?

The current stock price of Enveric Biosciences (ENVB) is $0.325 as of December 20, 2024.

What is the market cap of Enveric Biosciences (ENVB)?

The market cap of Enveric Biosciences (ENVB) is approximately 3.3M.

What does Enveric Biosciences specialize in?

Enveric Biosciences specializes in developing neuroplastogenic small-molecule therapeutics for treating depression, anxiety, and addiction disorders.

What is EB-003?

EB-003 is Enveric's lead program designed to promote neuroplasticity in treating mental health disorders without inducing hallucinations.

What is EB-002?

EB-002, formerly known as EB-373, is a next-generation synthetic prodrug of psilocin being developed for the treatment of psychiatric disorders.

Where is Enveric Biosciences headquartered?

Enveric Biosciences is headquartered in the United States.

How does Enveric Biosciences fund its research?

Enveric Biosciences maintains a robust financial foundation through transparent funding efforts to support its research initiatives.

Is Enveric involved in any partnerships or collaborations?

Yes, Enveric forms strategic partnerships and collaborations to enhance its research capabilities and accelerate its therapeutic programs.

How does Enveric ensure its treatments do not cause hallucinations?

Enveric focuses on non-hallucinogenic solutions, as evidenced by its lead program, EB-003, which promotes neuroplasticity without causing hallucinations.

What technologies is Enveric investing in?

Enveric is investing in cutting-edge technologies such as artificial intelligence (AI) to advance its research and development efforts.

What are the core values of Enveric Biosciences?

Enveric Biosciences is committed to ethical practices, patient-centric solutions, and innovative research to address mental health challenges.

Why is Enveric considered a key player in the biotech sector?

Enveric is emerging as a key player due to its pioneering approaches to mental health treatments and significant investments in innovative research.

Enveric Biosciences, Inc.

Nasdaq:ENVB

ENVB Rankings

ENVB Stock Data

3.32M
9.59M
6.93%
7.06%
3.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NAPLES